Whitehead L, Fell J T, Collett J H, Sharma H L, Smith A
Department of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester M13 9PL, UK.
J Control Release. 1998 Oct 30;55(1):3-12. doi: 10.1016/s0168-3659(97)00266-6.
Gastroretentive dosage forms have potential for use as controlled-release drug delivery systems. The use of floating dosage forms (FDFs) is one method to achieve prolonged gastric residence times (GRTs), providing opportunity for both local and systemic drug action. Multiple-unit systems avoid the 'all-or-nothing' gastric emptying nature of single-unit systems. A freeze-dried calcium alginate multiple-unit FDF has been developed which demonstrated favourable in vitro floating characteristics. The aim of this study was to investigate the in vivo behaviour of this system compared to a multiple-unit non-floating dosage form manufactured from identical material. The study was performed in seven healthy volunteers, who swallowed the radiolabelled formulations after a standard breakfast. Transit was monitored by gamma-scintigraphy and subjects were maintained in the fed state. Prolonged GRTs of over 5.5 h were achieved in all subjects for the floating formulations, which remained high up in the stomach for the whole of the test period. In contrast, the non-floating beads displayed short GRTs, with a mean onset emptying time of 1 h. The results of this study suggest that, in the fed state, this FDF has potential for sustained drug delivery for either local or systemic purposes.
胃滞留剂型有作为控释药物递送系统使用的潜力。使用漂浮剂型(FDFs)是实现延长胃滞留时间(GRTs)的一种方法,为局部和全身药物作用提供了机会。多单元系统避免了单单元系统“全或无”的胃排空特性。已开发出一种冻干海藻酸钙多单元FDF,其在体外显示出良好的漂浮特性。本研究的目的是将该系统与由相同材料制成的多单元非漂浮剂型相比,研究其体内行为。该研究在7名健康志愿者中进行,他们在标准早餐后吞下放射性标记制剂。通过γ闪烁扫描监测转运情况,受试者保持进食状态。所有受试者服用漂浮制剂后均实现了超过5.5小时的延长GRTs,在整个测试期间,制剂在胃上部保持高位。相比之下,非漂浮微丸显示出较短的GRTs,平均开始排空时间为1小时。本研究结果表明,在进食状态下,这种FDF有用于局部或全身目的的持续药物递送的潜力。